NA
ELDN icon

Navellier & Associates’s Eledon Pharmaceuticals ELDN Stock Holding History

Navellier & Associates’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$142K Buy
+35,925
New +$131K 0.01% 317

Other funds holding ELDN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Triumph Capital Management Denver, Colorado $552M AUM 20.75% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
PAM
Prodigy Asset Management Omaha, Nebraska $332M AUM 10.57% 1-Year Est. Return
DSC
Daytona Street Capital Saint Louis, Missouri $137M AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
PNFS
PW Nova Financial Services Newtown, Pennsylvania $466M AUM

Navellier & Associates's ELDN Position: Q2 2026 in Review

Navellier & Associates opened a new position in Eledon Pharmaceuticals (ELDN) in Q2 2026: 35,925 shares worth $142K. The stake represents 0.01% of the portfolio and ranks #317 among its holdings.

62 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Navellier & Associates held 35,925 shares of Eledon Pharmaceuticals worth $142K as of Q2 2026.
  • Eledon Pharmaceuticals was a new Navellier & Associates position in Q2 2026.
  • Eledon Pharmaceuticals made up 0.01% of Navellier & Associates's portfolio in Q2 2026, its #317 holding.
  • 62 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Navellier & Associates's 13F filing for Q2 2026, filed 4 Aug 2026.